Saturday, May 21, 2022
HomeLatest Pharma-NewsAstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment

January 13, 2022: “AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).

A total of 35 abstracts from AstraZeneca will be featured across the two meetings. There will be two oral presentations at ASCO GI taking place 20 to 22 January, and an additional two oral presentations at ASCO GU taking place 17 to 19 February.

- Advertisement -

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “There is an urgent need for new effective treatment options to delay disease recurrence and improve survival for patients with advanced liver, biliary tract and prostate cancers.

Our data for Imfinzi and Lynparza at these two meetings will illustrate how AstraZeneca is extending the benefits of our medicines into new areas where progress for patients has been limited.”

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca, said: “Our data will demonstrate the potential of our medicines to transform patient outcomes in liver, biliary tract and prostate cancers.

Results from HIMALAYA and TOPAZ-1 will underscore our commitment to improving long-term survival for patients with liver and biliary tract cancers, and data from PROpel will raise the bar in treating 1st-line metastatic castration-resistant prostate cancer.”

Aiming to transform treatment of liver and biliary tract cancers with immunotherapy combinations at ASCO GI
A late-breaking presentation will feature results from the HIMALAYA Phase III trial showing a statistically significant and clinically meaningful overall survival (OS) benefit with a single priming dose of tremelimumab added to Imfinzi (durvalumab) in 1st-line unresectable liver cancer.

This trial used a novel dose and schedule called the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen.

HIMALAYA is the first Phase III trial to show that a dual immunotherapy regimen has improved OS in this setting.

A second late-breaking presentation will highlight results from the TOPAZ-1 Phase III trial for Imfinzi plus chemotherapy in advanced biliary tract cancer, which was unblinded early at an interim analysis in October 2021 due to clear evidence of efficacy.

The combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone in 1st-line advanced biliary tract cancer, making it the first immunotherapy combination to demonstrate superior clinical outcomes over standard of care in a global, randomised trial in this setting.

Also at the meeting, the first data from Imfinzi plus bevacizumab in the Study 22 Phase II trial will provide the efficacy and safety profile of this combination in unresectable liver cancer.

This regimen is being tested in the EMERALD-1 Phase III trial of transarterial chemoembolisation in combination with Imfinzi alone and with bevacizumab in patients with locoregional liver cancer, as well as in the EMERALD-2 Phase III trial with liver cancer patients who are at high risk of recurrence after curative hepatic resection or ablation.

Challenging the status quo in prostate cancer with an industry-leading PARP inhibitor at ASCO GU
A late-breaking presentation will showcase the results from the PROpel Phase III trial of Lynparza (olaparib) plus abiraterone, which showed the combination significantly delayed disease progression in 1st-line metastatic castration-resistant prostate cancer (mCRPC) regardless of biomarker status. Lynparza is the first PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in this setting.

Additionally, an oral presentation will feature the results of the BAYOU Phase II trial evaluating the combination of Lynparza and Imfinzi in unresectable, Stage IV bladder cancer.

Data will show comparable efficacy of Imfinzi monotherapy to that of other immune checkpoint monotherapy data in similar trial populations and will suggest additional research into a potential role for PARP inhibition in subsets of patients with specific gene mutations.

Harnessing the potential of antibody drug conjugates across HER2-targetable cancers
At ASCO GI, data will include an encore presentation of the OS results of the DESTINY-Gastric01 Phase II trial of Enhertu (trastuzumab deruxtecan) in HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma (GEJA), and initial results from the DESTINY-Gastric03 Phase Ib/II trial in HER2-positive gastric cancer and GEJA.

In January 2021, Enhertu became the first HER2-directed medicine approved for patients with gastric cancer in a decade.

Additional Enhertu data at ASCO GI will include encore results from the DESTINY-CRC01 Phase II trial showing clinically meaningful activity in HER2-positive unresectable and/or metastatic colorectal cancer. The overall safety and tolerability profile of Enhertu in DESTINY-CRC01 was consistent with that seen in previously reported Enhertu trials. There are currently no medicines approved to specifically treat HER2-positive colorectal cancer.

At ASCO GU, results will be shared from the primary analysis of a Phase Ib trial of Enhertu in combination with nivolumab in HER2-expressing bladder cancer.

Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza,andwith Daiichi Sankyo Company Limited to develop and commercialise Enhertu.

Key AstraZeneca presentations during ASCO GI 2022

Lead authorAbstract titlePresentation details
Immuno-Oncology
Alfa-Abou, GKPhase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Abstract Presentation 3Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract21 January 202217:07 – 17:17 ET22:07 – 22:17 GMT
Oh, D-YA phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.Abstract Presentation 2Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract21 January 202216:45 – 16:55 ET21:45 – 22:55 GMT
Wang, LA phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Antibody drug conjugates
Yamaguchi, KTrastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).Rapid Abstract Session A: Cancers of the Esophagus and Stomach
Janjigian, YYDose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Meric-Bernstam, FA phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02). Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract 
Yoshino, TTrastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus
Raghav, KPSTrastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Key AstraZeneca presentations during ASCO GU 2022

Lead authorAbstract titlePresentation details
Immuno-Oncology
Rosenberg, JEBAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).Oral Abstract Session B: Urothelial Carcinoma18 February 202217:42 – 17:52 ET22:42 – 22:52 GMT
Powles, TA phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).Trials in Progress Poster Session B: Urothelial Carcinoma
DNA Damage Response
Saad, FPROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Oral Abstract Session A: Prostate Cancer17 February 202216:00 – 16:10 ET21:00 – 21:10 GMT 

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-liver-biliary-tract-and-prostate-cancer-treatment-with-practice-changing-imfinzi-and-lynparza-data-at-asco-gi-and-gu.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular